Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PRX III CRISPR Activation Plasmid (h): sc-401730-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PRX III CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- PRX III CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PRX III CRISPR Activation Plasmid (h) and PRX III CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PRDX3 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PRX III Antibody (1): sc-130336
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRX III CRISPR Activation Plasmid (h) | sc-401730-ACT | 20 µg | $397.00 |
PRDX3 encodes human peroxiredoxin III (PRX III), a mitochondria-localized thioredoxin-dependent peroxidase that detoxifies hydrogen peroxide and lipid hydroperoxides to maintain redox homeostasis. By limiting mitochondrial reactive oxygen species, PRX III supports oxidative phosphorylation, preserves mitochondrial membrane integrity, and influences redox-sensitive signaling pathways that modulate metabolism, apoptosis, and inflammatory responses. Altered PRDX3 expression or activity is frequently studied in the context of oxidative stress biology, mitochondrial dysfunction, and redox adaptation associated with cancer, neurodegeneration, and cardiometabolic disease mechanisms. As a key component of the mitochondrial antioxidant network, PRX III is commonly used to interrogate ROS-driven changes in gene expression, bioenergetics, and stress-response pathways.
PRX III CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PRDX3 expression without altering the underlying DNA sequence.
PRX III CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PRDX3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PRDX3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PRX III expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PRDX3 locus and enabling the study of PRX III-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PRX III pathway restoration in tumor cells with silenced or reduced PRDX3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.